The GLP1R/GIPR dual agonist NNC 00902746 (Novo Nordisk) significantly improved hemoglobin A1c (A1c) in T2DM (a reduction of 0.96% vs placebo) over a 12-week period, accompanied by a reduction in body weight
The FDA-approved prescribing instructions for both Ozempic and Wegovy require patients to begin at a low starting dose and increase it gradually over several weeks a process called titration
We already know the short-term side effects that patients taking these drugs to lose weight have experienced: nausea, vomiting, bloating, and some more extreme (albeit rare) things like bowel obstruction, pancreatitis, and stomach paralysis
It is always a good idea to take breaks and check in with a healthcare professional for longer-term use
This is why the bioavailability estimates for sublingual tirzepatide range so widely
Heres whats really happening, why it occurs, and how to manage it safely